Sep 26, 2018
Indivior Provides Update on Key Business Drivers and Expectations
Jul 31, 2018
Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld
Jul 27, 2018
FDA Approves PERSERIS(TM) (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Jun 28, 2018
Indivior's Temporary Restraining Order is Extended
May 31, 2018
Indivior Receives Subpoena from California Department of Insurance
May 25, 2018
Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence
May 14, 2018
Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case
Apr 20, 2018
Indivior Announces New Drug Submission to Health Canada for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder
Apr 05, 2018
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers
Mar 29, 2018
Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program
Feb 08, 2018
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers
Jan 03, 2018
Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABA(B) PAMs for Addiction Disorder Treatments
Dec 12, 2017
Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot
Nov 30, 2017
FDA Approves SUBLOCADE(TM) (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder
Oct 31, 2017
FDA Advisory Committees Recommend Approval of Indivior's RBP-6000 for the Treatment of Opioid Use Disorder